Rapid advances in oncology are creating innovative treatment options producing very successful outcomes for some patients. These novel cancer therapies are also creating significant payment challenges for health care purchasers and health insurance subscribers. These challenges have sparked interest in new payment arrangements to maximize the value of spending on these drugs.
This special NEHI Live! on October 26, 2017, explored the prospects for value-based purchasing in oncology. NEHI President and CEO Susan Dentzer moderated the discussion with Claire Brunken, Executive Director of Outcomes Projects for Novartis, and Dr. Michael Sherman, Chief Medical Officer and Senior Vice President of Harvard Pilgrim Healthcare.
